Cure of Histiocytic Lymphoma
Authors: JOHN E. ULTMANN
Journal: Annals of Internal Medicine (1982)

Editorials1 August 1982Cure of Histiocytic LymphomaJOHN E. ULTMANN, M.D.JOHN E. ULTMANN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-97-2-274 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe curability of patients with Hodgkin's disease of all stages improved from a 5-year survival rate in 1940 of 6% to a 5-year actuarial estimated survival rate in 1970 of over 75% (1). During this same 30-year period the survival statistics reported for "reticulum cell sarcoma" (the diagnostic entity coded in national statistical analyses before acceptance of the term "histiocytic lymphoma") remained at a dismal 5-year survival rate of 18% or lower (2).The knowledge gained from the cure of Hodgkin's disease together with new conceptual approaches and the development of new drugs and drug combinations have permitted novel approaches...References1. DEVITA V. The consequences of the chemotherapy of Hodgkin's Disease: the 10th David A. Karnofsky Memorial Lecture. Cancer. 1981;47:1-13. CrossrefMedlineGoogle Scholar2. CANTORFRAUMENI KJ. Distribution of non-Hodgkin's lymphoma in the United States between 1950 and 1975. Cancer Res. 1980;40:2645-52. MedlineGoogle Scholar3. SWEETKINZIEGAEKEGOLOMBFERGUSONULTMANN DJMHDJ. Survival of patients with localized diffuse histiocytic lymphoma. Blood. 1981;58:1218-23. CrossrefMedlineGoogle Scholar4. SWEETGOLOMBULTMANN DHJ. Cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. Ann Intern Med. 1980;92:785-90. LinkGoogle Scholar5. LEVITTBLOOMFIELDFRIZZERALEE SCGC. Curative radiotherapy for localized diffuse histiocytic lymphoma. Cancer. 1980;31(suppl II):237-41. Google Scholar6. CABANILLASBODYFREIREICH FGE. Management with chemotherapy only of stage I & II malignant lymphoma of aggressive histologic types. Cancer. 1980;46:2356-9. CrossrefMedlineGoogle Scholar7. MILLERJONES TS. Chemotherapy or chemotherapy with adjuvant radiotherapy for localized diffuse lymphoma. In: JONES SE, SALMON SE, eds. Adjuvant Therapy of Cancer II. New York: Grune & Stratton; 1979:155. Google Scholar8. BONADONNALATTUADAMONFARDINIMILANIBANFI GASFA. Combined radiotherapy-chemotherapy in localized non-Hodgkin's lymphomas: 5-year results of a randomized study. In: JONES SE, SALMON SE, eds. Adjuvant Therapy of Cancer II. New York: Grune & Stratton; 1979:145. Google Scholar9. ROSENBERG S. Current concepts in cancer: non-Hodgkin's lymphoma—selection of treatment on the basis of histologic type. N Engl J Med. 1979;301:924-8. CrossrefMedlineGoogle Scholar10. LESTERFULLERCONRAD JLF. The roles of staging laparotomy, chemotherapy, and radiotherapy in the management of localized diffuse large cell lymphoma: a study of 75 patients. Cancer. 1982;49:1746-53. CrossrefMedlineGoogle Scholar11. LAURENCECOLEMANALLENSILVERPASMANTIER JMSRM. Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six drug COP-BLAM regimen. Ann Intern Med. 1982;97:190-5. LinkGoogle Scholar12. LUKESCOLLINS RR. Immunologic characteristics of human malignant lymphomas. Cancer. 1974;34:1488-503. CrossrefGoogle Scholar13. . National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of working formulation for clinical usage. Cancer. 1982;49:2112-35. CrossrefMedlineGoogle Scholar14. STRAUCHENYOUNGDEVITAANDERSONFANTOREBERARD JRVTJC. Clinical relevance of the histopathological subclassification of diffuse "histiocytic" lymphoma. N Engl J Med. 1978;299:1382-6. CrossrefMedlineGoogle Scholar15. BLOOMFIELDGAJL-PECZALSKAFRIZZERAKERSEYGOLDMAN CKGJA. Clinical utility of lymphocyte surface markers combined with the Lukes-Collins histologic classification in adult lymphoma. N Engl J Med. 1979;301:512-8. CrossrefMedlineGoogle Scholar16. KOZINERLITTLEPASSE BCS. Treatment of advanced diffuse histiocytic lymphoma: an analysis of prognostic variables. Cancer. 1982;49:1571-9. CrossrefMedlineGoogle Scholar17. MILLERVARIAKOJISBITRAN JDJ. Diffuse histiocytic lymphoma with sclerosis: a clinicopathologic entity frequently causing superior venacaval obstruction. Cancer. 1981;47:748-56. CrossrefMedlineGoogle Scholar18. FISHERHUBBARDDEVITA RSV. Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood. 1981;58:45-51. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Department of Medicine and Cancer Research Center University of Chicago Chicago, Illinois PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByPrognostic factors in primary gastrointestinal non-Hodgkin's lymphoma. A multivariate analysis, report of 106 cases, and review of the literatureMaligne Non-Hodgkin-Lymphome: Erscheinungsformen und BehandlungDiffuse Histiocytic LymphomaBARRY H. KAPLAN, M.D. 1 August 1982Volume 97, Issue 2Page: 274-275KeywordsDiffuse large B-cell lymphomaDrug research and developmentDrugsHodgkin lymphomaMedical servicesResearch fundingSarcomaSurvival analysis Issue Published: 1 August 1982 PDF DownloadLoading ...